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OBJECTIVE: Bleeding and its complications cause pain,
disability and lead to a dramatic impairment of the hemo-
philiacs’ quality of life (QoL). Problems become extreme
when hemophiliacs develop inhibitory antibodies com-
promising the efﬁcacy of treatment: recent therapeutic
advances are likely to have improved this situation, with
a sensitive increasing of health care cost. Our objective
was to estimate the economic burden and QoL of hemo-
philiacs with inhibitors in Italy. METHODS: We con-
ducted a longitudinal, prospective, prevalence-based,
multicentre Cost Of Care Inhibitors Study (COCIS),
observing hemophiliacs patients with inhibitors for 18
months. Costs were evaluated from the point of view of
the Italian National Health Service (NHS). QoL was mea-
sured by the means of EQ-5D and SF-36 questionnaires.
RESULTS: Fifty-two hemophiliacs (median age 34.8,
15–64) were enrolled, almost all severe and high respond-
ing inhibitors. The orthopedic functioning resulted
impaired in 98% of patients. Eighty-one percent had at
least one bleeding event average (0.60/patient/month).
Eleven surgical procedures (6 for joint replacements), 30
hospitalizations, 712 out patients visits and 702 physio-
therapy sessions were recorded during the study period.
The cost of care to the NHS was €18,000/month/patient,
99% due to treatment products. Recombinant activated
factor VII represented 50% of total medical cost, one half
of it used for surgical interventions. Patients showed an
important impairment of physical health perception,
while psycological QoL was comparable to that in the
Italian general population. QoL of the COCIS patients
resulted not different from that in severe hemophiliacs
without inhibitors. CONCLUSIONS: Hemophilia with
inhibitors represents an example of a rare disease that
requires high amounts of resources. Effective and expen-
sive care of hemophilia with inhibitors provides a satis-
factory quality of life.
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OJECTIVES: The cost-effectiveness of four different
wound care dressings used in the treatment of delayed
healing venous leg ulcers was analysed in context of 
UK settings. I.e. three antiseptic dressings: A) a silver 
containing foam; B) an iodine containing paste; C) a
silver/charcoal containing cloth; and D) one foam dress-
ing without antiseptic properties. METHODS: Two
health economic models were designed (a Markov cohort
and a spreadsheet) and effectiveness data were collected
from published clinical data. All analyses had the per-
spective of the Health care sector. The timeframes for the
two analyses were four weeks for the spreadsheet model
and six months for the Markov model. Endpoints used in
the analyses were reduction in wound area and number
of healed wounds. An independent UK clinical expert
panel validated methods, cost, resource, and clinical data
as well as treatment practice used in the analyses. Sensi-
tivity analyses were undertaken. RESULTS: The cost of
weekly treatment with dressing A was £120 compared to
£146–187 for the other dressing alternatives. The cost per
percentage reduction (4 weeks spreadsheet) and the cost
per healed wound (6 months Markov model) were 
for dressing A £9 and £1228, respectively. The costs for
the other dressing alternatives ranged from £12–17 and
£1970–2339 respectively. Sensitivity analyses showed
that the results were robust. Nursing time costs combined
with the dressing frequency changes had a major effect
on the results. CONCLUSION: Treatment of delayed
healing chronic venous leg ulcers in the UK is associated
with relatively large costs. Dressing A proved to be cost-
effective in treatment of delayed healing venous leg ulcers,
the use of which, is expected to result in actual savings in
the health care sector.
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OBJECTIVES: The aim of the study was to investigate
resource use and type of local wound treatment in
patients with venous leg ulcers (VLU) in Sweden and 
to estimate the annual costs for leg ulcer patients.
METHODS: Weekly resource use data for local wound
treatment and details of surgical procedures were col-
lected from a clinical survey (138 patients) in specialist
care, primary health care, and home health care. Annual
costs were calculated from the weekly resource usage
multiplied by unit costs and published epidemiological
prevalence data for Sweden. RESULTS: Frequency of
dressing changes was 2.7 per week and compression was
used in 93% of the patients. Most dressing changes were
performed in the patients home (66%) and about 80%
